Novartis, the Swiss pharmaceutical giant, is proposing to buy Avidity Biosciences at a price exceeding $70 per share.
Back
Novartis, the Swiss pharmaceutical giant, is proposing to buy Avidity Biosciences at a price exceeding $70 per share.